Caribou Biosciences, Inc. (CRBU) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $1.68 (+0.90%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 4, 2025 | Asthika Goonewardene | Truist Financial | $7.00 | +317.9% |
| Jun 3, 2024 | Liisa Bayko | Evercore ISI | $3.00 | +79.1% |
Top Analysts Covering CRBU
CRBU vs Sector & Market
| Metric | CRBU | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +212.5% | +11474.8% | +17.1% |
| P/E Ratio | -1.33 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $2M | $2M | $2M | 3 |
| 2026-09-30 | $2M | $2M | $2M | 1 |
| 2026-12-31 | $19M | $19M | $19M | 2 |
| 2027-12-31 | $6M | $25M | $43M | 4 |
| 2028-12-31 | $9M | $27M | $74M | 5 |
| 2029-12-31 | $23M | $74M | $199M | 2 |
| 2030-12-31 | $51M | $164M | $444M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.35 | $-0.34 | $-0.33 | 2 |
| 2026-09-30 | $-0.36 | $-0.36 | $-0.36 | 1 |
| 2026-12-31 | $-0.22 | $-0.22 | $-0.22 | 1 |
| 2027-12-31 | $-1.35 | $-1.30 | $-1.24 | 3 |
| 2028-12-31 | $-1.91 | $-1.51 | $-1.15 | 5 |
| 2029-12-31 | $-5.57 | $-1.74 | $-0.19 | 1 |
| 2030-12-31 | $-5.89 | $-1.84 | $-0.20 | 1 |
Frequently Asked Questions
What is the analyst consensus for CRBU?
The consensus among 3 analysts covering Caribou Biosciences, Inc. (CRBU) is Buy with an average price target of $5.00.
What is the highest price target for CRBU?
The highest price target for CRBU is $7.00, set by Asthika Goonewardene at Truist Financial on 2025-11-04.
What is the lowest price target for CRBU?
The lowest price target for CRBU is $3.00, set by Liisa Bayko at Evercore ISI on 2024-06-03.
How many analysts cover CRBU?
3 analysts have issued ratings for Caribou Biosciences, Inc. in the past 12 months.
Is CRBU a buy or sell right now?
Based on 3 analyst ratings, CRBU has a consensus rating of Buy (2.00/5) with a +212.5% upside to the consensus target of $5.00.
What are the earnings estimates for CRBU?
Analysts estimate CRBU will report EPS of $-0.34 for the period ending 2026-06-30, with revenue estimated at $2M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.